BURLINGTON, Mass., March 17/PRNewswire-FirstCall/ --
Palomar Medical Technologies Inc (Nasdaq: PMTI) is a leading researcher and
developer of proprietary laser and other light-based systems for hair removal
and other cosmetic treatments. The Company will be presenting its latest
products at the American Academy of Dermatology's 61st Annual Meeting, in San
Francisco, CA, from March 21 to 26, 2003, and will be available to give
investor demonstrations and discuss our full line of products at booth #2801.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO )
At the meeting, Palomar will announce a new platform and a number of new
and exciting hand pieces for additional cosmetic applications and upgrades for
the Palomar EsteLux pulsed-light system and the Palomar Q-YAG 5 laser system.
The Palomar EsteLux pulsed-light system, in addition to the hand pieces being
introduced this week, is currently sold with the LuxY hand piece for hair
removal and pigmented lesion treatment on large body areas; the LuxG hand
piece for photofacial treatments on vascular and pigmented lesions; the LuxR
hand piece for large-area hair removal on all skin types; and the LuxRs hand
piece for permanent hair reduction on all skin types with fewer treatments.
The Palomar Q-YAG 5 laser system is sold for tattoo and pigmented lesion
removal. Physicians can now offer their patients a variety of affordable
cosmetic light-based treatments. This family of products has helped the
Company increase its revenues and profit over the last year.
Palomar's light-based cosmetic technology is among the most advanced in
the industry. Palomar invested considerable resources to ensure that its
patent portfolio and other intellectual property provide strong protection of
its technology.
To reserve a time to meet with Palomar management and/or receive product
demonstrations, please contact Jay McKeage, Account Manager at Palomar's
investor relations' firm Allen & Caron, Inc., at 212-691-8087 or
jay@allencaron.com.
About Palomar Medical Technologies Inc: Palomar is a leading researcher
and developer of light-based systems for hair removal and other cosmetic
treatments. Recently, Palomar and The Gillette Company (NYSE: G) entered into
an agreement to complete development and commercialize a patented home-use,
light-based hair removal device for women. New and exciting indications are
being tested to further advance the hair removal market and other cosmetic
applications. Palomar pioneered the optical hair removal field, when, in 1996,
it introduced the first high-powered laser hair removal system. Since then,
many of the major advances in light-based hair removal have been based on
Palomar technology. There are now millions of light-based hair removal
procedures performed around the world every year in physician offices,
clinics, spas and salons.
For more information on Palomar and its products, visit Palomar's website
at http://www.palmed.com. To continue receiving the most up-to-date information and
latest news on Palomar as it happens, sign up to receive automatic e-mail
alerts by going to the E-mail Alerts page in the Investor Relations' section
of the website.
With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, development
and introduction of new products, and financial projections that involve risk
and uncertainties that may individually or mutually impact the matters herein,
and cause actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but are not
limited to, results of future operations, technological difficulties in
developing or introducing new products, the results of future research, lack
of product demand and market acceptance for current and future products, the
effect of economic conditions, challenges in managing joint ventures and
research with third parties, the impact of competitive products and pricing,
governmental regulations with respect to medical devices, including whether
FDA clearance will be obtained for future products, the results of litigation,
difficulties in collecting royalties, potential infringement of third-party
intellectual property rights, and/or other factors, which are detailed from
time to time in the Company's SEC reports, including the report on Form 10-K
for the year ended December 31, 2001 and the Company's quarterly reports on
Form 10-Q. Readers are cautioned not to place undue reliance on these forward-
looking statements, which speak only as of the date hereof. The Company
undertakes no obligation to release publicly the result of any revisions to
these forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
Contacts: Paul S. Weiner
Chief Financial Officer
Palomar Medical Technologies Inc
781-993-2411
ir@palmed.com
SOURCE Palomar Medical Technologies Inc
 back to top
Related links:
http://www.palmed.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/107555.html
CONTACT:
Paul S. Weiner, Chief Financial Officer of
Palomar Medical Technologies Inc, +1-781-993-2411, ir@palmed.com
|
